# Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

> **NCT01736189** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 346 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT01736189
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-11
- **Primary completion:** 2018-04-16
- **Final completion:** 2018-04-16
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01736189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01736189, "Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01736189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*